

# Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection

Antonio F. Pardiñas<sup>1</sup>, Peter Holmans<sup>1</sup>, Andrew J. Pocklington<sup>1</sup>, Valentina Escott-Price<sup>1</sup>, Stephan Ripke<sup>2,3</sup>, Noa Carrera<sup>1</sup>, Sophie E. Legge<sup>1</sup>, Sophie Bishop<sup>1</sup>, Darren Cameron<sup>1</sup>, Marian L. Hamshere<sup>1</sup>, Jun Han<sup>1</sup>, Leon Hubbard<sup>1</sup>, Amy Lynham<sup>1</sup>, Kiran Mantripragada<sup>1</sup>, Elliott Rees<sup>1</sup>, James H. MacCabe<sup>4</sup>, Steven A. McCarroll<sup>5</sup>, Bernhard T. Baune<sup>6</sup>, Gerome Breen<sup>7,8</sup>, Enda M. Byrne<sup>9,10</sup>, Udo Dannlowski<sup>11</sup>, Thalia C. Eley<sup>7</sup>, Caroline Hayward<sup>12</sup>, Nicholas G. Martin<sup>13,14</sup>, Andrew M. McIntosh<sup>15,16</sup>, Robert Plomin<sup>7</sup>, David J. Porteous<sup>12</sup>, Naomi R. Wray<sup>9,10</sup>, Armando Caballero<sup>17</sup>, Daniel H. Geschwind<sup>18</sup>, Laura M. Huckins<sup>19</sup>, Douglas M. Ruderfer<sup>19</sup>, Enrique Santiago<sup>20</sup>, Pamela Sklar<sup>19</sup>, Eli A. Stahl<sup>19</sup>, Hyejung Won<sup>18</sup>, Esben Agerbo<sup>21,22</sup>, Thomas D. Als<sup>21,23,24</sup>, Ole A. Andreassen<sup>25,26</sup>, Marie Bækvad-Hansen<sup>21,27</sup>, Preben Bo Mortensen<sup>21,22,23</sup>, Carsten Bøcker Pedersen<sup>21,22</sup>, Anders D. Børglum<sup>21,23,24</sup>, Jonas Bybjerg-Grauholm<sup>21,27</sup>, Srdjan Djurovic<sup>28,29</sup>, Naser Durmishi<sup>30</sup>, Marianne Giørtz Pedersen<sup>21,22</sup>, Vera Golimbet<sup>31</sup>, Jakob Grove<sup>21,23,24,32</sup>, David M. Hougaard<sup>21,27</sup>, Manuel Mattheisen<sup>21,23,24</sup>, Espen Molden<sup>33</sup>, Ole Mors<sup>21,34</sup>, Merete Nordentoft<sup>21,35</sup>, Milica Pejovic-Milovancevic<sup>36</sup>, Engilbert Sigurdsson<sup>37</sup>, Teimuraz Silagadze<sup>38</sup>, Christine Søholm Hansen<sup>21,27</sup>, Kari Stefansson<sup>39</sup>, Hreinn Stefansson<sup>39</sup>, Stacy Steinberg<sup>39</sup>, Sarah Tosato<sup>40</sup>, Thomas Werge<sup>21,41,42</sup>, GERAD1 Consortium<sup>43</sup>, CRESTAR Consortium<sup>43</sup>, David A. Collier<sup>7,44</sup>, Dan Rujescu<sup>45,46</sup>, George Kirov<sup>1</sup>, Michael J. Owen<sup>1\*</sup>, Michael C. O'Donovan<sup>1\*</sup> and James T. R. Walters<sup>1\*</sup>

**Schizophrenia is a debilitating psychiatric condition often associated with poor quality of life and decreased life expectancy. Lack of progress in improving treatment outcomes has been attributed to limited knowledge of the underlying biology, although large-scale genomic studies have begun to provide insights. We report a new genome-wide association study of schizophrenia (11,260 cases and 24,542 controls), and through meta-analysis with existing data we identify 50 novel associated loci and 145 loci in total. Through integrating genomic fine-mapping with brain expression and chromosome conformation data, we identify candidate causal genes within 33 loci. We also show for the first time that the common variant association signal is highly enriched among genes that are under strong selective pressures. These findings provide new insights into the biology and genetic architecture of schizophrenia, highlight the importance of mutation-intolerant genes and suggest a mechanism by which common risk variants persist in the population.**

Schizophrenia is characterized by psychosis and negative symptoms such as social and emotional withdrawal. While onset of psychosis typically does not occur until late adolescence or early adulthood, there is strong evidence from clinical and epidemiological studies that schizophrenia reflects a disturbance of neurodevelopment<sup>1</sup>. It confers substantial mortality and morbidity, with a mean reduction in life expectancy of 15–30 years<sup>2,3</sup>. Although recovery is possible, most patients have poor social and functional outcomes<sup>4</sup>. No substantial improvements in outcomes have emerged since the advent of antipsychotic medication in the mid-twentieth century, a fact that has been attributed to a lack of knowledge of pathophysiology<sup>1</sup>.

Schizophrenia is both highly heritable and polygenic, with risk ascribed to variants spanning the full spectrum of population frequencies<sup>5–7</sup>. The relative contributions of alleles of various frequencies are not fully resolved, but recent studies estimate that common alleles, captured by genome-wide association study (GWAS) arrays, explain between one-third and one-half of the genetic variance in liability<sup>8</sup>. There has been a long-standing debate, from an evolutionary standpoint, as to how common risk alleles persist in the population, particularly given the early mortality and decreased fecundity associated with schizophrenia<sup>9</sup>. Various hypotheses have been proposed, including compensatory advantage (balancing selection), whereby schizophrenia-associated alleles confer reproductive

advantages in particular contexts<sup>10,11</sup>; hitchhiking, whereby risk-associated alleles are maintained by their linkage to positively selected alleles<sup>12</sup>; and contrasting theories that attribute these effects to rare variants and gene–environment interaction<sup>13</sup>. Addressing these competing hypotheses is now tractable given advances from recent studies of common genetic variation in schizophrenia.

The largest published schizophrenia GWAS, that from the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC), identified 108 genome-wide significant loci and unequivocally demonstrated the value of increasing sample sizes for discovery in schizophrenia genetics research<sup>5</sup>. Here we report a large, phenotypically homogeneous GWAS of schizophrenia that, when combined with previously published data, identifies new facets of genetic architecture and biology and demonstrates that the evolutionary process of background selection contributes to the persistence of common risk alleles in the population.

## Results

**GWAS and meta-analysis.** We obtained genome-wide genotype information for schizophrenia cases from the UK (the CLOZUK sample), which we combined with control datasets obtained from public repositories or through collaboration. The final sample size was 11,260 cases and 24,542 controls (5,220 cases and 18,823 controls not in previous schizophrenia GWAS; Methods and Supplementary Figs. 1 and 2). At a genome-wide level, the association statistics indicated that the common variant architecture in the CLOZUK sample was highly correlated with that in an independent sample of 29,415 cases and 40,101 controls from the PGC (genetic correlation =  $0.954 \pm 0.030$ ;  $P = 6.63 \times 10^{-227}$ ), and this was further confirmed by polygenic risk score and trend test analyses across the datasets at a range of association  $P$ -value thresholds (Methods and Supplementary Tables 1 and 2).

Meta-analysis of the CLOZUK and independent PGC datasets, excluding related and overlapping samples (total of 40,675 cases and 64,643 controls; Supplementary Fig. 3) identified 179 independent genome-wide significant SNPs ( $P < 5 \times 10^{-8}$ ; Supplementary Table 3) mapping to 145 independent loci (Fig. 1, Methods and Supplementary Table 4). The 145 associated loci included 93 of those that were genome-wide significant in the study of the PGC, the majority of which showed a strengthened association (Supplementary Fig. 4 and Supplementary Table 5). This does not imply that the remaining 15 PGC loci were false positives; rather, this reflects the expected inflation of effect sizes for genome-wide significant SNPs in incompletely powered studies and, as we demonstrate, is consistent with all 108 PGC loci representing true positives (Supplementary Note). Of the 52 loci not identified by the PGC, 2 have been reported as genome-wide significant in other studies: the locus at *ZEB2*<sup>14</sup> and a locus on chromosome 8 (38.0–38.3 Mb)<sup>15</sup>.

In further independent samples (5,662 cases and 154,224 controls), 43 of the 50 genome-wide significant index SNPs showed the same pattern of allelic association, a level that far surpassed chance ( $P = 1.05 \times 10^{-7}$ ). Despite the modest number of cases in these samples, 18 of the 50 index alleles reached nominal significance ( $P < 0.05$ ), which again is implausible by chance ( $P = 1.46 \times 10^{-11}$ ). None demonstrated evidence for heterogeneity of effect (Methods and Supplementary Table 6).

**Mutation-intolerant genes.** Recent studies have shown that mutation-intolerant genes capture much of the rare variant architecture of neurodevelopmental disorders such as autism, intellectual disability and developmental delay, as well as schizophrenia<sup>16–19</sup>. Here we show that, for schizophrenia, this also holds for common variation. Using gene set analysis in MAGMA<sup>20</sup>, loss-of-function (LoF)-intolerant genes ( $n = 3,230$ ) as defined by the Exome Aggregation Consortium (ExAC)<sup>21</sup> using their gene-level constraint metric (pLI  $\geq 0.9$ ), were enriched for common variant associations

with schizophrenia in comparison with all other annotated genes ( $P = 4.1 \times 10^{-16}$ ).


It has been shown that pLI is correlated with gene expression across tissues, including brain<sup>21</sup>, which raises the possibility that the enrichment for LoF-intolerant genes in schizophrenia may reflect enrichment for signal in genes expressed in the brain. However, LoF-intolerant gene set enrichment was robust to the inclusion of both ‘brain-expressed’ ( $n = 10,360$ ) and ‘brain-specific’ ( $n = 2,647$ ) gene sets<sup>19</sup> as covariates in the analysis ( $P = 1.89 \times 10^{-10}$ ) or to controlling for FPKM gene expression values in brain<sup>22</sup> ( $P = 1.03 \times 10^{-14}$ ).

It has been suggested that clustering of risk alleles in mutation-intolerant genes is a hallmark of early-onset traits under natural selection<sup>23,24</sup>. However, LoF-intolerant genes are known to be enriched for SNPs identified as genome-wide significant in GWAS (as listed in the NHGRI-EBI GWAS Catalog<sup>25</sup>) and for broad categories of disorders<sup>21</sup>. To examine whether our finding is a property of polygenic disorders in general, we obtained summary genetic data from a late-onset neuropsychiatric disorder (Alzheimer’s disease), a non-psychiatric disorder (type 2 diabetes) and a psychological trait (neuroticism), each of which has been shown to be under minimal selective pressure (Methods). These other phenotypes showed at best a weak signal for enrichment of the LoF-intolerant gene set in the MAGMA analysis, with the signal not comparable to that seen in schizophrenia (Alzheimer’s disease,  $P = 0.008$ ; type 2 diabetes,  $P = 0.016$ ; neuroticism,  $P = 0.066$ ).

To quantify the contribution of SNPs within LoF-intolerant genes to schizophrenia SNP-based heritability ( $h^2_{\text{SNP}}$ ), we used partitioned linkage disequilibrium score regression (LDSR)<sup>26</sup> (Supplementary Table 7). Overall, genic SNPs accounted for 64% of  $h^2_{\text{SNP}}$ , a 1.23-fold enrichment proportional to their SNP content ( $P = 5.93 \times 10^{-14}$ ). Consistent with the analysis using MAGMA,  $h^2_{\text{SNP}}$  was enriched in LoF-intolerant genes (2.01-fold;  $P = 2.78 \times 10^{-24}$ ), which explained 30% of all  $h^2_{\text{SNP}}$  (equating to 47% of all genic  $h^2_{\text{SNP}}$ ). In contrast, genes classed as not LoF intolerant (pLI  $< 0.9$ ) were significantly depleted for  $h^2_{\text{SNP}}$  relative to their SNP content (0.90-fold;  $P = 5.86 \times 10^{-3}$ ), although in absolute terms SNPs in these genes accounted for 34% of  $h^2_{\text{SNP}}$ . A finer-scale analysis of the relationship between LoF intolerance scores and enrichment for association showed that enrichment was restricted to genes with a pLI score above 0.9, precisely those defined as ‘LoF intolerant’ (Supplementary Fig. 5).

**Common risk alleles in regions under background selection.** Our finding that LoF-intolerant genes are enriched for common risk variants raises the question of how such alleles are found at common frequencies in the population. While the contribution of ultra-rare variation in functionally important genes to disorders associated with low fecundity can be accounted for by de novo mutation<sup>16,19,27</sup>, this cannot explain the persistence of common alleles. To address this question, we used partitioned LDSR to test the relationship between schizophrenia-associated alleles and SNP-based signatures of natural selection. These included measures of positive selection, background selection and Neanderthal introgression. We examined the heritability of SNPs after thresholding them at extreme values for these metrics (top 2%, 1% and 0.5%), including in the baseline model annotation sets such as LoF-intolerant genes and genomic regions with extreme LD patterns (Methods).

We observed strong evidence for schizophrenia  $h^2_{\text{SNP}}$  enrichment in SNPs under strong background selection (BGS), which was consistent across all the thresholds we examined (Table 1). We also found a significant depletion of  $h^2_{\text{SNP}}$  in SNPs subject to positive selection as indexed by the CLR statistic. These two results are mutually consistent, as calculation of the CLR statistic explicitly controls for the effect of BGS<sup>28</sup>. This suggests that SNPs under positive selection, but under weak or no BGS, are depleted for association with schizophrenia. No significant relationship between  $h^2_{\text{SNP}}$  and other positive selection or Neanderthal introgression measures



**Fig. 1 | Manhattan plot of schizophrenia GWAS associations.** Associations are shown from the meta-analysis of CLOZUK and an independent PGC dataset ( $n = 105,318$ ; 40,675 cases and 64,643 controls). The 145 genome-wide significant loci are highlighted in green. The red horizontal line indicates the genome-wide statistical significance threshold ( $P = 5 \times 10^{-8}$ ).

was found after correction for multiple testing (Table 1). An LDSR analysis treating BGS measures as a quantitative trait rather than as a binary one confirmed that the relationship between BGS and schizophrenia association was not due to the imposition of arbitrary thresholds to define strong BGS ( $P = 7.73 \times 10^{-11}$ ). We also note that the  $\tau_c$  statistic of the LDSC model was significant for BGS, in both the binary ( $P = 0.041$ ) and quantitative ( $P = 0.023$ ) analyses (Supplementary Table 8). The  $\tau_c$  statistic indicates the enrichment of BGS after controlling for all other annotations in the model (including LoF-intolerant genes)<sup>26</sup> and thus represents a robust and conservative test for BGS enrichment.

The above analyses account for a possible confounding relationship between LoF intolerance and BGS. To illustrate this more clearly, we binned the BGS intensities into four categories of increasing score and classified SNPs in these bins according to whether they were in LoF-intolerant genes, 'all other' gene sets or a non-genic set (Supplementary Fig. 6). Note that the lower boundary of the top bin (BGS intensity  $> 0.75$ ) corresponds approximately to the top 2% BGS threshold in Table 1 and is equivalent to a reduction in effective population size estimated at each SNP of 75% or more<sup>29</sup>. We found significant heritability enrichment across all BGS intensity intervals in LoF-intolerant genes that increased progressively with higher intensity scores. Notably, we also found heritability enrichment for SNPs under BGS pressure in genes that were not LoF intolerant, restricted to the highest BGS intensity bin. Indeed, the highest BGS intensity bin in non-LoF-intolerant genes was enriched for heritability at a level roughly equivalent to that for all LoF-intolerant genes.

These findings point to BGS and LoF intolerance as making at least partially independent contributions to heritability enrichment in schizophrenia. In contrast, none of the phenotypes we selected on the basis of their minimal impact on fecundity (Alzheimer's disease, type 2 diabetes and neuroticism) showed significant BGS enrichment for heritability either when using the BGS  $\tau_c$  statistic of the LDSR model (minimum  $P > 0.22$ ; Supplementary Table 8) or when specifically testing regions of high BGS intensity in genes that were tolerant ( $pLI < 0.9$ ) of functional mutations (minimum  $P > 0.40$ ).

**Systems genomics.** Using MAGMA, we undertook a primary analysis of 134 central nervous system (CNS)-related gene sets we have previously shown capture the excess copy number variation (CNV) burden in schizophrenia<sup>30</sup>. In a GWAS context, we now show that, collectively, this group of gene sets captures a disproportionately high fraction of  $h^2_{\text{SNP}}$  (30% of total heritability, enrichment = 1.63,  $P = 8.57 \times 10^{-13}$ , 46% of genic heritability; Supplementary Table 7). Of the 134 sets, 54 were nominally significant, of which 12 survived multiple-testing correction (family-wise error rate (FWER)  $P < 0.05$ ; Supplementary Table 9), with no notable association for gene sets such as the ARC protein complex and the NMDAR protein network, that we have previously implicated in rare variant studies<sup>30,31</sup>. Stepwise conditional analysis, adjusting sequentially for the more strongly associated gene sets, resulted in six gene sets that were independently associated with schizophrenia (Table 2 and Supplementary Data). These extended from low-level molecular and subcellular processes to broad behavioral phenotypes. The

**Table 1 | Heritability analysis of natural selection metrics**

Metric	Ref.	Top 2% of scores (genome wide)		Top 1% of scores (genome wide)		Top 0.5% of scores (genome wide)	
		Enrichment	2-sided <i>P</i> value	Enrichment	2-sided <i>P</i> value	Enrichment	2-sided <i>P</i> value
Background selection ( <i>B</i> statistic)	[29]	<b>1.801</b>	<b>0.001</b>	<b>2.341</b>	<b>9.90 × 10<sup>-4</sup></b>	<b>2.365</b>	<b>0.002</b>
Positive selection (CLR)	[28]	<b>0.408</b>	<b>6.53 × 10<sup>-5</sup></b>	<b>0.173</b>	<b>5.80 × 10<sup>-7</sup></b>	0.259	0.016
Positive selection (CMS)	[88]	<b>0.054</b>	<b>0.001</b>	-0.037	0.006	-0.039	0.007
Positive selection (XP-EEH)	[87]	0.621	0.342	0.383	0.303	0.125	0.268
Positive selection (iHS)	[86]	0.973	0.946	0.980	0.974	1.633	0.557
Neanderthal posterior probability (LA)	[89]	0.807	0.347	0.800	0.462	0.858	0.745

Partitioned LDSR regression results for SNPs thresholded by extreme values (defined as top percentiles versus all other SNPs) of each natural selection metric. All tests have been adjusted for 58 'baseline' annotations, which include categories such as LoF intolerant, recombination coldspot and conserved (Methods). Enrichment values below 1 indicate a depletion of  $h^2_{SNP}$  in an annotation category (less contribution than expected for a given number of SNPs). Negative enrichments should be considered zero (no contribution to  $h^2_{SNP}$  by these SNPs). Bold values indicate results surviving correction after adjusting for all tests (Bonferroni  $\alpha=0.05/18=0.0028$ ).

most strongly associated gene set constituted the targets of the fragile X mental retardation protein (FMRP)<sup>32</sup>. FMRP is a neuronal RNA-binding protein that interacts with polyribosomal mRNAs (the 842 target transcripts of this gene set<sup>32</sup>) and is thought to act by inhibiting translation of target mRNAs, including many transcripts of pre- and postsynaptic proteins. The FMRP target set has been shown to be enriched for rare mutational burden in exome sequencing studies of de novo variation in autism<sup>33</sup> and intellectual disability<sup>31</sup>. In schizophrenia, it has also been shown to be nominally significantly enriched for association signal in sequencing studies<sup>8,31</sup> and GWAS<sup>5,8</sup>, but has only inconsistently been associated in studies of CNV<sup>30,34</sup>. Here we provide the strongest evidence thus far for enrichment of this gene set in schizophrenia.

We highlight another five gene sets that are independently associated with schizophrenia. Three of these derive from the Mouse Genome Informatics (MGI) database<sup>35</sup> and relate to behavioral and neurophysiological correlates of learning: abnormal behavior (MP:0004924), abnormal nervous system electrophysiology (MP:0002272) and abnormal long-term potentiation (MP:0002207). We note that two of these gene sets (MP:0004924 and MP:0002207)

were among the five most enriched of the 134 gene sets tested in a recent schizophrenia CNV analysis<sup>30</sup>. The remaining two independently associated gene sets were voltage-gated calcium channel complexes<sup>36</sup> and the 5-HT<sub>2C</sub> receptor complex<sup>37</sup>. The calcium channel finding confirms extensive evidence from common and rare variant studies implicating calcium channel genes in schizophrenia<sup>5,8</sup>, including a new GWAS locus in *CACNA1D* identified in our meta-analysis. While there is less convergent evidence in support of the involvement of the 5-HT<sub>2C</sub> receptor complex in schizophrenia, the fact that we identify independent association for this gene set implicates these genes in schizophrenia pathophysiology and potentially rejuvenates a previous avenue of 5-HT<sub>2C</sub> ligand therapeutic endeavor in schizophrenia research<sup>38</sup>. However, we interpret this result with caution given the small size of this gene set and the fact that a number of its genes encode synaptic proteins that are structurally related to other receptor complexes<sup>37</sup>, not only 5-HT<sub>2C</sub>.

**Systems genomics and mutation-intolerant genes.** The LoF-intolerant genes and the six conditionally independent ('significant') CNS-related gene sets together account for 39% of schizophrenia SNP-based heritability ( $P=5.07 \times 10^{-26}$ ), equating to 61% of genic heritability (Fig. 2a and Supplementary Table 7). This is likely to be an underestimation of the true effect of these gene sets, as distal non-genic regulatory elements (not included in this analysis) will add to the heritability explained by these genes. In examining the relationship between the LoF-intolerant and CNS-related gene sets (Fig. 2a), genes belonging to both categories were the most highly enriched (2.6-fold,  $P=7.90 \times 10^{-15}$ ), although LoF-intolerant genes that were not annotated to our significant CNS gene sets still displayed enrichment for SNP-based heritability (1.74-fold,  $P=9.77 \times 10^{-10}$ ), while genes that were in the significant CNS gene sets but had pLI < 0.9 showed more modest enrichment (1.39-fold,  $P=6.05 \times 10^{-4}$ ). Notably, genes outside these categories were depleted in heritability relative to their SNP content (enrichment = 0.79,  $P=1.82 \times 10^{-7}$ ).


This general pattern remained when we focused on the six significant CNS gene sets individually, in that the enrichment in these gene sets derived primarily from their intersection with LoF-intolerant genes (Fig. 2b). Indeed, only the targets of FMRP showed significant enrichment for SNPs in genes that were not LoF intolerant (2.06-fold,  $P=4.23 \times 10^{-5}$ ).

**Data-driven gene set analysis.** To set the systems genomics results in context and to ensure that we were not missing enrichment in other gene sets by our hypothesis-driven approach, we undertook a purely data-driven analysis of a larger comprehensive annotation

**Table 2 | Functional gene set analysis highlights six independent gene sets associated with schizophrenia**

Gene set	Number of genes	Enrichment <i>P</i> value (FWER) <sup>a</sup>	Conditional <i>P</i> value <sup>b</sup>
Targets of FMRP <sup>32</sup>	798	1 × 10 <sup>-5</sup>	1.9 × 10 <sup>-8</sup>
Abnormal behavior (MP:0004924)	1,939	1.8 × 10 <sup>-4</sup>	1.4 × 10 <sup>-5</sup>
5-HT <sub>2C</sub> receptor complex <sup>37</sup>	16	0.029	0.001
Abnormal nervous system electrophysiology (MP:0002272)	201	0.003	0.002
Voltage-gated calcium channel complexes <sup>36</sup>	196	0.011	0.016
Abnormal long-term potentiation (MP:0002207)	142	0.030	0.031

MP refers to Mammalian Phenotype Ontology terms of the MGI<sup>35</sup>, from which gene sets were derived. FMRP, fragile X mental retardation protein. <sup>a</sup>Westfall-Young family-wise error rate, as implemented in MAGMA<sup>20</sup>. <sup>b</sup>From stepwise conditional analysis that adjusts sequentially for 'stronger' associated gene sets.



**Fig. 2 | Partitioned heritability analysis of gene sets in schizophrenia.** **a**, Heritability of genomic partitions and the six conditionally independent ('significant') gene sets (Table 2). The radius of each segment indicates the degree of enrichment, while the arc (angle of each slice) indicates the percentage of total SNP-based heritability explained. No relative enrichment (enrichment = 1) is shown by the dashed red line (and depletion equates to enrichment < 1, inside red line). **b**, Heritability of the significant CNS gene sets dissected by their overlap with LoF-intolerant genes. Whiskers represent heritability or enrichment standard errors. Asterisks indicate the significance of each heritability enrichment (\* $P \leq 0.05$ , \*\* $P \leq 0.01$ , \*\*\* $P \leq 0.001$ ).

of gene sets from multiple public databases, totaling 6,677 gene sets (Methods and Supplementary Table 10). Six gene sets survived FWER correction for the full 6,677 gene sets and showed independence through conditional analyses. The LoF-intolerant gene set was the most strongly enriched, followed by the two most strongly associated functional gene sets we had specified in our hypothesis-driven CNS gene set analysis (FMRP targets and MGI abnormal behavior genes). The other three sets were calcium ion import (GO:0070509), membrane depolarization during action potential (GO:0086010) and synaptic transmission (GO:0007268). These are highly overlapping with the independently associated sets from our primary CNS systems genomics analysis. Indeed, if we repeat the

data-driven comprehensive gene set analysis while adjusting for the six independently associated CNS gene sets, the only surviving enrichment term is the LoF-intolerant genes. These results are consistent with those from CNV analysis<sup>30</sup> in that they do not support annotations other than those related to CNS function and demonstrate that hypothesis-based analysis to maximize power does not substantially impact the overall pattern of results.

**Identifying likely candidates within associated loci.** To identify SNPs and genes that might be causally linked to the genome-wide significant associations, we used FINEMAP<sup>39</sup> to identify credibly causal alleles (those with a cumulative posterior probability for

a locus of at least 95%) and functionally annotated these alleles using ANNOVAR<sup>40</sup>. This identified 6,105 credible SNPs across 144 genome-wide significant loci, excluding the major histocompatibility complex (MHC) region (Methods and Supplementary Table 11). From these, we defined a highly credible set of SNPs ( $n=25$ ) as those that were more likely to explain the associations than all other SNPs combined (i.e., with a FINEMAP posterior probability greater than 0.5). Of these, 14 mapped to genes on the basis of putative functionality (exonic SNPs that cause nonsynonymous or splice variations or promoter SNPs;  $n=6$ ) or mapped to regions identified as likely regulatory elements ( $n=8$ ) through chromosome conformation analysis performed in tissue from the developing brain using Hi-C<sup>41</sup> physical interactions (Methods and Supplementary Table 12). One of the implicated alleles was a nonsynonymous variant in the manganese and zinc transporter gene *SLC39A8*. Nonsynonymous variants in this gene, which lead to *SLC39A8* deficiency, have been associated with severe neurodevelopmental disorders putatively through impaired manganese transport and glycosylation<sup>42</sup>, highlighting a mechanism of therapeutic potential for schizophrenia.

We also applied Summary-data-based Mendelian Randomization (SMR) analysis<sup>43</sup> to the data in concert with dorsolateral prefrontal cortex expression quantitative trait locus (eQTL) data from the CommonMind Consortium<sup>44</sup>, aiming to identify variants that might be causally linked through expression changes in specific genes (Methods and Supplementary Table 13). After applying a conservative threshold ( $P_{\text{HEIDI}} > 0.05$ ) that prioritized colocalized signals due to a single causal variant<sup>43</sup>, we identified 22 candidates at 19 loci with false discovery rate (FDR)  $P < 0.05$ .

In total, the combination of FINEMAP, Hi-C and SMR analyses assigned potentially causal genes at 33 genome-wide significant loci and implicated a single gene at 27 of these loci. However, the analyses intersect for only a single gene, *ZNF823*, indicating the need for more comprehensive functional genomic annotations in CNS-relevant tissues.

## Discussion

In the largest genetic study of schizophrenia thus far, we explore the genomic architecture of and the evolutionary pressures on common variants associated with the disorder. Our study provides the first evidence linking common variation in LoF-intolerant genes to risk of developing schizophrenia and demonstrates that these genes account for a substantial proportion (30%) of the SNP-based heritability for schizophrenia. Systems genomics analysis highlights six gene sets that are independently associated with schizophrenia and point to molecular, physiological and behavioral pathways involved in schizophrenia pathogenesis.

Given that mutation intolerance is due to high selection pressure<sup>21,23,24</sup>, our finding that schizophrenia risk variants that persist at common allele frequencies are enriched in LoF-intolerant genes might appear counterintuitive. However, new evidence presented here suggests that this can be reconciled by BGS, which is a consequence of purifying selection in regions of low recombination<sup>45,46</sup>. In such regions, recurrent selection against deleterious variants causes haplotypes to be removed from the gene pool, which reduces genetic diversity in a manner equivalent to a reduction in effective population size<sup>47</sup>. This in turn impairs the efficiency of the selection process, allowing alleles with small deleterious effects to rise in frequency by drift<sup>48</sup>. Such a consequence of purifying selection has been shown to be compatible with the genomic architecture of complex human traits<sup>49</sup> and to influence phenotypes in model organisms<sup>50</sup>. We have explicitly modeled this effect (both theoretically and via simulations; Supplementary Note) and provide strong evidence for the feasibility of this effect as explanatory for the effect sizes seen for common alleles in schizophrenia.

We did not find enrichment for any measure of positive selection or Neanderthal introgression. A recent study explained a negative

correlation between schizophrenia associations and metrics indicative of a Neanderthal selective sweep as evidence for positive selection or polygenic adaptation in schizophrenia<sup>12</sup>. We do not find any significant correlation in our model, which addresses the contribution of BGS, and hence our results are not consistent with large contributions of positive selection to the genetic architecture of schizophrenia (Table 1). Indeed, positive selection is not widespread in humans, as reported by other studies that explicitly considered or accounted for BGS<sup>28,51</sup>. Polygenic adaptation, the co-occurrence of many subtle allele frequency shifts at loci influencing complex traits<sup>52</sup>, remains an intriguing possibility but has not been implicated in psychiatric phenotypes, including schizophrenia, in recent analyses<sup>53,54</sup>. In contrast, BGS has been proposed as a mechanism driving human–Neanderthal incompatibilities, as regions with stronger estimated BGS have lower estimated Neanderthal introgression<sup>55</sup>. We therefore conclude that the bulk of the BGS signal we obtain is unlikely to be influenced by positive selection<sup>29</sup>, challenging theories of the selective advantage of schizophrenia risk alleles to explain the high population frequencies of these alleles.

## Methods

Methods, including statements of data availability and any associated accession codes and references, are available at <https://doi.org/10.1038/s41588-018-0059-2>.

Received: 15 September 2017; Accepted: 7 January 2018;

Published online: 26 February 2018

## References

- Owen, M. J., Sawa, A. & Mortensen, P. B. Schizophrenia. *Lancet* **388**, 86–97 (2016).
- Thornicroft, G. Physical health disparities and mental illness: the scandal of premature mortality. *Br. J. Psychiatry* **199**, 441–442 (2011).
- Olfson, M., Gerhard, T., Huang, C., Crystal, S. & Stroup, T. S. Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry* **72**, 1172–1181 (2015).
- Morgan, C. et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. *Psychol. Med.* **44**, 2713–2726 (2014).
- Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421–427 (2014).
- Singh, T. et al. Rare loss-of-function variants in *SETD1A* are associated with schizophrenia and developmental disorders. *Nat. Neurosci.* **19**, 571–577 (2016).
- Rees, E. et al. Analysis of copy number variations at 15 schizophrenia-associated loci. *Br. J. Psychiatry* **204**, 108–114 (2014).
- Purcell, S. M. et al. A polygenic burden of rare disruptive mutations in schizophrenia. *Nature* **506**, 185–190 (2014).
- Power, R. A. et al. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or substance abuse vs their unaffected siblings. *JAMA Psychiatry* **70**, 22–30 (2013).
- Huxley, J., Mayr, E., Osmond, H. & Hoffer, A. Schizophrenia as a genetic morphism. *Nature* **204**, 220–221 (1964).
- Shaner, A., Miller, G. & Mintz, J. Schizophrenia as one extreme of a sexually selected fitness indicator. *Schizophr. Res.* **70**, 101–109 (2004).
- Srinivasan, S. et al. Genetic markers of human evolution are enriched in schizophrenia. *Biol. Psychiatry* **80**, 284–292 (2016).
- Uher, R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. *Mol. Psychiatry* **14**, 1072–1082 (2009).
- Ripke, S. et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat. Genet.* **45**, 1150–1159 (2013).
- Shi, Y. et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. *Nat. Genet.* **43**, 1224–1227 (2011).
- Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* **542**, 433–438 (2017).
- Kosmicki, J. A. et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. *Nat. Genet.* **49**, 504–510 (2017).
- Samochoa, K. E. et al. A framework for the interpretation of de novo mutation in human disease. *Nat. Genet.* **46**, 944–950 (2014).

19. Genovese, G. et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. *Nat. Neurosci.* **19**, 1433–1441 (2016).
20. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
21. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).
22. Fagerberg, L. et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol. Cell. Proteomics* **13**, 397–406 (2014).
23. Smith, N. G. C. & Eyre-Walker, A. Human disease genes: patterns and predictions. *Gene* **318**, 169–175 (2003).
24. Blekhman, R. et al. Natural selection on genes that underlie human disease susceptibility. *Curr. Biol.* **18**, 883–889 (2008).
25. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP–trait associations. *Nucleic Acids Res.* **42**, D1001–D1006 (2014).
26. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
27. Takata, A., Ionita-Laza, I., Gogos, J. A., Xu, B. & Karayiorgou, M. De novo synonymous mutations in regulatory elements contribute to the genetic etiology of autism and schizophrenia. *Neuron* **89**, 940–947 (2016).
28. Huber, C. D., DeGiorgio, M., Hellmann, I. & Nielsen, R. Detecting recent selective sweeps while controlling for mutation rate and background selection. *Mol. Ecol.* **25**, 142–156 (2016).
29. McVicker, G., Gordon, D., Davis, C. & Green, P. Widespread genomic signatures of natural selection in hominid evolution. *PLoS Genet.* **5**, e1000471 (2009).
30. Pocklington, A. J. et al. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. *Neuron* **86**, 1203–1214 (2015).
31. Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature* **506**, 179–184 (2014).
32. Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* **146**, 247–261 (2011).
33. Iossifov, I. et al. De novo gene disruptions in children on the autistic spectrum. *Neuron* **74**, 285–299 (2012).
34. Szatkiewicz, J. P. et al. Copy number variation in schizophrenia in Sweden. *Mol. Psychiatry* **19**, 762–773 (2014).
35. Blake, J. A., Bult, C. J., Eppig, J. T., Kadin, J. A. & Richardson, J. E. The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. *Nucleic Acids Res.* **42**, D810–D817 (2014).
36. Müller, C. S. et al. Quantitative proteomics of the Ca<sub>v</sub>2 channel nano-environments in the mammalian brain. *Proc. Natl. Acad. Sci. USA* **107**, 14950–14957 (2010).
37. Bécamel, C. et al. Synaptic multiprotein complexes associated with 5-HT<sub>2C</sub> receptors: a proteomic approach. *EMBO J.* **21**, 2332–2342 (2002).
38. Liu, J. et al. Prediction of efficacy of vabicaserin, a 5-HT<sub>2C</sub> agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. *CPT Pharmacometrics Syst. Pharmacol.* **3**, e111 (2014).
39. Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
40. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164–e164 (2010).
41. Won, H. et al. Chromosome conformation elucidates regulatory relationships in developing human brain. *Nature* **538**, 523–527 (2016).
42. Park, J. H. et al. SLC39A8 deficiency: a disorder of manganese transport and glycosylation. *Am. J. Hum. Genet.* **97**, 894–903 (2015).
43. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
44. Fromer, M. et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. *Nat. Neurosci.* **19**, 1442–1453 (2016).
45. Charlesworth, B. The effects of deleterious mutations on evolution at linked sites. *Genetics* **190**, 5–22 (2012).
46. Charlesworth, B., Betancourt, A. J., Kaiser, V. B. & Gordo, I. Genetic recombination and molecular evolution. *Cold Spring Harb. Symp. Quant. Biol.* **74**, 177–186 (2009).
47. Cameron, J. M., Williford, A. & Kliman, R. M. The Hill–Robertson effect: evolutionary consequences of weak selection and linkage in finite populations. *Heredity* **100**, 19–31 (2008).
48. Charlesworth, B. Background selection 20 years on: the Wilhelmine E. Key 2012 Invitational Lecture. *J. Hered.* **104**, 161–171 (2013).
49. North, T. L. & Beaumont, M. A. Complex trait architecture: the pleiotropic model revisited. *Sci. Rep.* **5**, 9351 (2015).
50. Rockman, M. V., Skrovanek, S. S. & Kruglyak, L. Selection at linked sites shapes heritable phenotypic variation in *C. elegans*. *Science* **330**, 372–376 (2010).
51. Vitti, J. J., Grossman, S. R. & Sabeti, P. C. Detecting natural selection in genomic data. *Annu. Rev. Genet.* **47**, 97–120 (2013).
52. Stephan, W. Signatures of positive selection: from selective sweeps at individual loci to subtle allele frequency changes in polygenic adaptation. *Mol. Ecol.* **25**, 79–88 (2016).
53. Field, Y. et al. Detection of human adaptation during the past 2000 years. *Science* **354**, 760–764 (2016).
54. Key, F. M., Fu, Q., Romagné, F., Lachmann, M. & Andrés, A. M. Human adaptation and population differentiation in the light of ancient genomes. *Nat. Commun.* **7**, 10775 (2016).
55. Harris, K. & Nielsen, R. The genetic cost of Neanderthal introgression. *Genetics* **203**, 881–891 (2016).

## Acknowledgements

**General.** This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement 279227 (CRESTAR Consortium). The work at Cardiff University was funded by the Medical Research Council (MRC) Centre (MR/L010305/1), a program grant (G0800509) and a project grant (MR/L011794/1) and by the European Community's Seventh Framework Programme HEALTH-F2-2010-241909 (project FOR2107 DA1151/5-1; SFB-TRR58, project C09) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/012/17). E.M.B. and N.R.W. received salary funding from the National Health and Medical Research Council (NHMRC; 1078901, 105363). E. Santiago and A.C. received funding from the Agencia Estatal de Investigación (AEI; CGL2016-75904-C2-1-P), Xunta de Galicia (ED431C 2016-037) and Fondo Europeo de Desarrollo Regional (FEDER). The iPSYCH and GEMS2 teams acknowledge funding from the Lundbeck Foundation (grants R102-A9118 and R155-2014-1724), the Stanley Medical Research Institute, an advanced grant from the European Research Council (project 294838), the Danish Strategic Research Council and grants from Aarhus University to the iSEQ and CIRRAU centers.

**Case data.** We thank the participants and clinicians who took part in the CardiffCOGS study. For the CLOZUK2 sample, we thank Leyden Delta for supporting the sample collection, anonymization and data preparation (particularly M. Helthuis, J. Jansen, K. Jollie and A. Colson), Magna Laboratories, UK (A. Walker) and, for CLOZUK1, Novartis and the Doctor's Laboratory staff for their guidance and cooperation. We acknowledge L. Bates, C. Bresner and L. Hopkins, at Cardiff University, for laboratory sample management. We acknowledge W. Lawrence and M. Einon, at Cardiff University, for support with the use and setup of computational infrastructures.

**Control data.** A full list of the investigators who contributed to the generation of the Wellcome Trust Case Control Consortium (WTCCC) data is available from its website. Funding for the project was provided by the Wellcome Trust under award 076113. The UK10K project was funded by Wellcome Trust award WT091310. Venous blood collection for the 1958 Birth Cohort (NCDS) was funded by UK MRC grant G0000934, peripheral blood lymphocyte preparation was funded by the Juvenile Diabetes Research Foundation (JDRF) and the Wellcome Trust, and cell line production, DNA extraction and processing were funded by Wellcome Trust grant 06854/Z/02/Z. Genotyping was supported by the Wellcome Trust (083270) and the European Union (ENGAGE: HEALTH-F4-2007-201413). The UK Blood Services Common Controls (UKBS-CC collection) was funded by the Wellcome Trust (076113/C/04/Z) and by a National Institute for Health Research (NIHR) programme grant to the NHS Blood and Transplant authority (NHSBT; RP-PG-0310-1002). NHSBT also made possible the recruitment of the Cardiff Controls, from participants who provided informed consent. Generation Scotland (GS) received core funding from the Chief Scientist Office of the Scottish government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland, and was funded by the MRC and Wellcome Trust (grant 10436/Z/14/Z). The Type 1 Diabetes Genetics Consortium (T1DGC; EGA dataset EGAS00000000038) is a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the National Human Genome Research Institute (NHGRI), the National Institute of Child Health and Human Development (NICHD) and JDRF. The People of the British Isles project (POBI) is supported by the Wellcome Trust (088262/Z/09/Z). TwinsUK is funded by the Wellcome Trust, MRC, European Union, NIHR-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. Funding for the QIMR samples was provided by the Australian NHMRC (241944, 339462, 389875, 389891, 389892, 389938, 442915, 442981, 496675, 496739, 552485, 552498, 613602, 613608, 613674, 619667), the Australian Research Council (FT0991360, FT0991022), the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254) and the US National Institutes of Health (NIH; AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, MH666206, DA12854, DA019951) and the Center for Inherited Disease Research (Baltimore, MD, USA). TEDS is supported by a program grant from the MRC (G0901245-G0500079), with additional support from the NIH (HD044454, HD059215). In the GERAD1 Consortium, Cardiff University was supported by the Wellcome Trust,

the MRC, Alzheimer's Research UK (ARUK) and the Welsh government. King's College London acknowledges support from the MRC. The University of Belfast acknowledges support from ARUK, the Alzheimer's Society, Ulster Garden Villages, the Northern Ireland R&D Office and the Royal College of Physicians/Dunhill Medical Trust. Washington University was funded by NIH grants, the Barnes Jewish Foundation, and the Charles and Joanne Knight Alzheimer's Research Initiative. The Bonn group was supported by the German Federal Ministry of Education and Research (BMBF), Competence Network Dementia and Competence Network Degenerative Dementia and by the Alfried Krupp von Bohlen und Halbach-Stiftung.

### Author contributions

A.F.P. curated and processed genetic data, performed statistical analyses, contributed to the interpretation of results and participated in the primary drafting of the manuscript. P.H., A.J.P., V.E.-P., A.C. and E. Santiago performed statistical analyses, contributed to the interpretation of results and participated in the primary drafting of the manuscript. S.R. curated and processed genetic data and participated in the primary drafting of the manuscript. N.C. and M.L.H. contributed to the interpretation of results and participated in the primary drafting of the manuscript. S.E.L., S.B. and A.L. participated in the recruitment of participants for the study and curated and managed their phenotypic information. D.C., J.H., L.H., E.R. and G.K. contributed and curated data used in the statistical analyses. K.M. managed the laboratory and genotyping procedures at Cardiff University. J.H.M., D.A.C. and D.R. supervised the recruitment of the participants for the study. S.A.M. managed the genotyping of samples for the study. N.R.W. contributed genotypes of control samples and participated in the primary drafting of the manuscript. Control data were obtained from the GERAD1 Consortium; as such, the investigators within the GERAD1 Consortium contributed to the design

and implementation of GERAD1 and/or provided control data but did not participate in analysis or writing of this report. D.H.G., L.M.H., D.M.R., P.S., E.A.S. and H.W. performed statistical analyses and contributed to the interpretation of results. M.J.O. and M.C.O'D. conceived and supervised the project, contributed to the interpretation of results and participated in the primary drafting of the manuscript. J.T.R.W. conceived and supervised the project, led the recruitment of the participants and sample acquisition for the study, performed statistical analysis, contributed to the interpretation of results and participated in the primary drafting of the manuscript. All other authors contributed genotypes of control samples or summary statistics of replication samples. All authors had the opportunity to review and comment on the manuscript, and all approved the final manuscript.

### Competing interests

D.A.C. is a full-time employee and stockholder of Eli Lilly and Company. The remaining authors declare no conflicts of interest.

### Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41588-018-0059-2>.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Correspondence and requests for materials** should be addressed to M.J.O. or M.C.O. or J.T.R.W.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<sup>1</sup>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK. <sup>2</sup>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. <sup>3</sup>Department of Psychiatry and Psychotherapy, Charité, Campus Mitte, Berlin, Germany. <sup>4</sup>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. <sup>5</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. <sup>6</sup>Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia. <sup>7</sup>MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. <sup>8</sup>NIHR Biomedical Research Centre for Mental Health, Maudsley Hospital and Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. <sup>9</sup>Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia. <sup>10</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia. <sup>11</sup>Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany. <sup>12</sup>Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. <sup>13</sup>School of Psychology, University of Queensland, Brisbane, Queensland, Australia. <sup>14</sup>QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. <sup>15</sup>Division of Psychiatry, University of Edinburgh, Edinburgh, UK. <sup>16</sup>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK. <sup>17</sup>Departamento de Bioquímica, Genética e Inmunología. Facultad de Biología, Universidad de Vigo, Vigo, Spain. <sup>18</sup>Department of Neurology, Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. <sup>19</sup>Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>20</sup>Departamento de Biología Funcional. Facultad de Biología, Universidad de Oviedo, Oviedo, Spain. <sup>21</sup>iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark. <sup>22</sup>National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark. <sup>23</sup>iSEQ, Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark. <sup>24</sup>Department of Biomedicine-Human Genetics, Aarhus University, Aarhus, Denmark. <sup>25</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway. <sup>26</sup>NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. <sup>27</sup>Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. <sup>28</sup>NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway. <sup>29</sup>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. <sup>30</sup>Department of Child and Adolescent Psychiatry, University Clinic of Psychiatry, Skopje, Macedonia. <sup>31</sup>Department of Clinical Genetics, Mental Health Research Center, Moscow, Russia. <sup>32</sup>Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark. <sup>33</sup>Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. <sup>34</sup>Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark. <sup>35</sup>Mental Health Services in the Capital Region of Denmark, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark. <sup>36</sup>Department of Psychiatry, School of Medicine, University of Belgrade, Belgrade, Serbia. <sup>37</sup>Department of Psychiatry, National University Hospital, Reykjavik, Iceland. <sup>38</sup>Department of Psychiatry and Drug Addiction, Tbilisi State Medical University (TSMU), Tbilisi, Georgia. <sup>39</sup>deCODE Genetics, Reykjavik, Iceland. <sup>40</sup>Section of Psychiatry, Department of Public Health and Community Medicine, University of Verona, Verona, Italy. <sup>41</sup>Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark. <sup>42</sup>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. <sup>43</sup>A list of members and affiliations appears at the end of the paper. <sup>44</sup>Discovery Neuroscience Research, Eli Lilly and Company, Lilly Research Laboratories, Windlesham, UK. <sup>45</sup>Department of Psychiatry, University of Halle, Halle, Germany. <sup>46</sup>Department of Psychiatry, University of Munich, Munich, Germany. \*e-mail: [owenmj@cardiff.ac.uk](mailto:owenmj@cardiff.ac.uk); [odonovanmc@cardiff.ac.uk](mailto:odonovanmc@cardiff.ac.uk); [waltersjt@cardiff.ac.uk](mailto:waltersjt@cardiff.ac.uk)



**GERAD1 Consortium:**

**Denise Harold<sup>47,48</sup>, Rebecca Sims<sup>47</sup>, Amy Gerrish<sup>47</sup>, Jade Chapman<sup>47</sup>, Valentina Escott-Price<sup>1</sup>, Richard Abraham<sup>47</sup>, Paul Hollingworth<sup>47</sup>, Jaspreet Pahwa<sup>47</sup>, Nicola Denning<sup>47</sup>, Charlene Thomas<sup>47</sup>, Sarah Taylor<sup>47</sup>, John Powell<sup>49</sup>, Petroula Proitsi<sup>49</sup>, Michelle Lupton<sup>49</sup>, Simon Lovestone<sup>49,50</sup>, Peter Passmore<sup>51</sup>, David Craig<sup>51</sup>, Bernadette McGuinness<sup>51</sup>, Janet Johnston<sup>51</sup>, Stephen Todd<sup>51</sup>, Wolfgang Maier<sup>52</sup>, Frank Jessen<sup>52</sup>, Reiner Heun<sup>52</sup>, Britta Schurmann<sup>52,53</sup>, Alfredo Ramirez<sup>52</sup>, Tim Becker<sup>54</sup>, Christine Herold<sup>54</sup>, André Lacour<sup>54</sup>, Dmitriy Drichel<sup>54</sup>, Markus Nothen<sup>55</sup>, Alison Goate<sup>56</sup>, Carlos Cruchaga<sup>56</sup>, Petra Nowotny<sup>56</sup>, John C. Morris<sup>56</sup>, Kevin Mayo<sup>56</sup>, Peter Holmans<sup>1</sup>, Michael O'Donovan<sup>1</sup>, Michael Owen<sup>1</sup> and Julie Williams<sup>47</sup>**

**CRESTAR Consortium:**

**Evanthia Achilla<sup>57</sup>, Esben Agerbo<sup>21,22</sup>, Cathy L. Barr<sup>58</sup>, Theresa Wimberly Böttger<sup>59</sup>, Gerome Breen<sup>7,8</sup>, Dan Cohen<sup>60</sup>, David A. Collier<sup>7,44</sup>, Sarah Curran<sup>61,62</sup>, Emma Dempster<sup>63</sup>, Danai Dima<sup>7</sup>, Ramon Sabes-Figuera<sup>57</sup>, Robert J. Flanagan<sup>64</sup>, Sophia Frangou<sup>65</sup>, Josef Frank<sup>66</sup>, Christiane Gasse<sup>59,67</sup>, Fiona Gaughran<sup>4</sup>, Ina Giegling<sup>45</sup>, Jakob Grove<sup>21,23,24,32</sup>, Eilis Hannon<sup>63</sup>, Annette M. Hartmann<sup>45</sup>, Barbara Heißer<sup>68</sup>, Marinka Helthuis<sup>69</sup>, Henriette Thisted Horsdal<sup>59</sup>, Oddur Ingimarsson<sup>70</sup>, Karel Jollie<sup>69</sup>, James L. Kennedy<sup>71</sup>, Ole Köhler<sup>33</sup>, Bettina Konte<sup>45</sup>, Maren Lang<sup>66</sup>, Sophie E. Legge<sup>1</sup>, Cathryn Lewis<sup>7</sup>, James MacCabe<sup>4</sup>, Anil K. Malhotra<sup>72</sup>, Paul McCrone<sup>57</sup>, Sandra M. Meier<sup>59</sup>, Jonathan Mill<sup>7,63</sup>, Ole Mors<sup>21,34</sup>, Preben Bo Mortensen<sup>21,22,23</sup>, Markus M. Nöthen<sup>55</sup>, Michael C. O'Donovan<sup>1</sup>, Michael J. Owen<sup>1</sup>, Antonio F. Pardiñas<sup>1</sup>, Carsten B. Pedersen<sup>21,22</sup>, Marcella Rietschel<sup>66</sup>, Dan Rujescu<sup>45,46</sup>, Ameli Schwalber<sup>68</sup>, Engilbert Sigurdsson<sup>70</sup>, Holger J. Sørensen<sup>35</sup>, Benjamin Spencer<sup>73</sup>, Hreinn Stefansson<sup>39</sup>, Henrik Støvring<sup>67</sup>, Jana Strohmaier<sup>66</sup>, Patrick Sullivan<sup>74,75</sup>, Evangelos Vassos<sup>7</sup>, Moira Verbelen<sup>7</sup>, James T. R. Walters<sup>1</sup> and Thomas Werge<sup>21,41,42</sup>**

<sup>47</sup>MRC Centre for Neuropsychiatric Genetics and Genomics, Neurosciences and Mental Health Research Institute, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK. <sup>48</sup>Neuropsychiatric Genetics Group, Department of Psychiatry, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland. <sup>49</sup>Institute of Psychiatry, Department of Neuroscience, King's College London, London, UK. <sup>50</sup>Department of Psychiatry, University of Oxford, Oxford, UK. <sup>51</sup>Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK. <sup>52</sup>Department of Psychiatry, University of Bonn, Bonn, Germany. <sup>53</sup>Institute for Molecular Psychiatry, University of Bonn, Bonn, Germany. <sup>54</sup>Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. <sup>55</sup>Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. <sup>56</sup>Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St. Louis, MO, USA. <sup>57</sup>Centre for Economics of Mental and Physical Health, Health Service and Population Research Department, Institute of Psychiatry, King's College London, London, UK. <sup>58</sup>Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada. <sup>59</sup>National Centre for Register-Based Research, Department of Economics and Business, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark. <sup>60</sup>Department of Community Mental Health, Mental Health Organization North-Holland North, Heerhugowaard, the Netherlands. <sup>61</sup>Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. <sup>62</sup>Brighton and Sussex Medical School, University of Sussex, Brighton, UK. <sup>63</sup>University of Exeter Medical School, RILD, University of Exeter, Exeter, UK. <sup>64</sup>Toxicology Unit, Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust, London, UK. <sup>65</sup>Clinical Neurosciences Studies Center, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>66</sup>Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany. <sup>67</sup>Centre for Integrated Register-based Research, CIRRAU, Aarhus University, Aarhus, Denmark. <sup>68</sup>Concentris Research Management, Fürstfeldbruck, Germany. <sup>69</sup>Leyden Delta, Nijmegen, the Netherlands. <sup>70</sup>Department of Psychiatry, Landspítali University Hospital, Reykjavik, Iceland. <sup>71</sup>Centre for Addiction and Mental Health, Toronto, Ontario, Canada. <sup>72</sup>Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health System, Glen Oaks, NY, USA. <sup>73</sup>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. <sup>74</sup>Center for Psychiatric Genomics, Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. <sup>75</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

## Methods

**GWAS and reporting of independently associated regions.** Details of sample collection and genotype quality control are given in the Supplementary Note. The CLOZUK schizophrenia GWAS was performed using logistic regression with imputation probabilities ('dosages') adjusted for 11 principal-component analysis (PCA) covariates. These covariates were chosen as those nominally significant ( $P < 0.05$ ) in a logistic regression for association with the phenotype<sup>56</sup>. To avoid overburdening the GWAS power by adding too many covariates to the regression model<sup>57</sup>, only the first 20 principal components were considered and tested for inclusion, as higher numbers only become useful for the analysis of populations that bear strong signatures of complex admixture<sup>58</sup>. The final set of covariates included the first five principal components (as recommended for most GWAS approaches<sup>59</sup>) and principal components 6, 9, 11, 12, 13 and 19. Quantile–quantile and Manhattan plots are shown in Supplementary Figs. 7 and 8.

To identify independent signals among the regression results, signals were amalgamated into putative associated loci using the same two-step strategy and parameters as PGC (Supplementary Table 14). In this procedure, regular LD clumping is performed ( $r^2 = 0.1$ ,  $P < 1 \times 10^{-4}$ ; window size  $< 3$  Mb) to obtain independent index SNPs. Afterward, loci are defined for each index SNP as the genomic region that contains all other imputed SNPs within the region with  $r^2 \geq 0.6$ . To avoid inflating the number of signals in gene-dense regions or in those with complex LD, all loci within 250 kb of each other were annealed.

**Meta-analysis with PGC.** A total of 6,040 cases and 5,719 controls from CLOZUK were included in the recent PGC study<sup>5</sup>. We reanalyzed the PGC data after excluding all these cases and controls, obtaining a sample termed 'INDEPENDENT PGC' (29,415 cases and 40,101 controls). Adding the summary statistics from this independent sample to the CLOZUK GWAS results allowed for a combined analysis of 40,675 cases and 64,643 controls (without duplicates or related samples). This meta-analysis was performed using the fixed-effects procedure in METAL<sup>60</sup> with weights derived from standard errors. For consistency with the PGC analysis, additional filters (INFO  $> 0.6$  and MAF  $> 0.01$ ) were applied to the CLOZUK and INDEPENDENT PGC summary statistics, leaving 8 million markers in the final meta-analysis results. Quantile–quantile and Manhattan plots are shown in Supplementary Fig. 3 and Fig. 2. The same procedure as above was used to report independent loci from this analysis (Supplementary Tables 3 and 4). As raw PGC genotypes were not available for the LD clumping procedure, phase 3 of the 1000 Genomes Project (1KGPp3) was used as a reference.

**Replication of new GWAS loci.** To validate the association signals from the CLOZUK + PGC meta-analysis, we amalgamated data contributed by other schizophrenia genetics consortia (total of 5,762 cases and 154,224 controls; details in the Supplementary Note). We sought GWAS summary statistic data for the index SNPs from the 50 new genome-wide significant loci (Supplementary Table 4). These summary statistics were subjected to meta-analysis in METAL using the fixed-effects procedure to obtain replication and heterogeneity statistics (Supplementary Table 6).

**Estimation and assessment of a polygenic signal.** Association signals caused by the vast polygenicity underlying complex traits can be hard to distinguish from confounders related to sample relatedness and population stratification. To effectively disentangle this issue, we used the software LD Score v1.0 to analyze the summary statistics of our association analyses and estimate the contribution of confounding biases to our results by LDSR<sup>61</sup>. An LD reference was generated from 1KGPp3 after restricting this dataset to strictly unrelated individuals and retaining only markers with MAF  $> 0.01$ . To improve accuracy, the summary statistics used as input were refined by discarding all indels and restricting SNPs to those with INFO  $> 0.9$  and MAF  $> 0.01$ , a total of 5.16 million SNPs. The resulting LD score intercept for the CLOZUK GWAS was  $1.085 \pm 0.010$ , which compared to a mean  $\chi^2$  of 1.417 indicates a polygenic contribution of at least 80%. For the CLOZUK + PGC meta-analysis, the LD score intercept was  $1.075 \pm 0.014$  (mean  $\chi^2 = 1.960$ ), which supports more than 90% of the signal being driven by polygenic architecture. Both of these figures are in line with those for other well-powered GWAS of complex human traits<sup>64</sup>, including schizophrenia<sup>5</sup>. This analysis was also used to calculate SNP-based heritability ( $h^2_{\text{SNP}}$ ) for our three datasets (CLOZUK, INDEPENDENT PGC and the CLOZUK + PGC meta-analysis), which we transformed to a liability scale using a population prevalence of 1% (registry-based lifetime prevalence<sup>62</sup>). For reference and compatibility with epidemiological studies of schizophrenia, prevalence estimates of 0.7% (lifetime morbid risk<sup>63</sup>) and 0.4% (point prevalence<sup>63</sup>, more akin to treatment-resistant schizophrenia prevalence (appropriate for CLOZUK)) were used for additional liability-scale  $h^2_{\text{SNP}}$  calculations (Supplementary Table 15).

The LDSR framework allowed us to compare the genetic architecture of CLOZUK and INDEPENDENT PGC, by calculating the correlation of their summary statistics<sup>64</sup>. A genetic correlation coefficient of  $0.954 \pm 0.030$  was obtained, with a  $P$  value of  $6.63 \times 10^{-227}$ . We also examined the independent SNPs that reached a genome-wide significant level in the INDEPENDENT PGC dataset, of which there were 76 after excluding the extended major histocompatibility complex (xMHC) region. In the CLOZUK sample, 76% ( $n = 57$ ) of these genome-

wide significant SNPs were nominally significant ( $P < 0.05$ ). Using binomial sign tests based on clumped subsets of SNPs<sup>65</sup>, we found that all but 1 (98.6%) of these 76 genome-wide significant SNPs were associated with the same direction of effect in the CLOZUK sample, a result highly unlikely to reflect chance ( $P = 2.04 \times 10^{-21}$ ; Supplementary Table 1). Moreover, of the 1,160 SNPs with an association  $P$  value less than  $1 \times 10^{-4}$  in the INDEPENDENT PGC sample, 82% showed enrichment in the CLOZUK cases ( $P = 3.44 \times 10^{-113}$ ), confirming that very large numbers of true associations will be discovered among these SNPs with increased sample sizes. Additionally, the new sample introduced in this study (CLOZUK2) was compared by the same methods with the PGC dataset and showed results consistent with the full CLOZUK analysis, providing molecular validation of this sample as a schizophrenia sample (Supplementary Table 1).

We went on to conduct polygenic risk score analysis. Polygenic scores for CLOZUK were generated from INDEPENDENT PGC as a training set, using the same parameters for risk profile score (RPS) analysis in PGC<sup>5</sup>, arriving at a high-confidence set of SNPs for RPS estimation by removing the xMHC region and indels, and applying INFO  $> 0.9$  and MAF  $> 0.1$  cutoffs. Scores were generated from the autosomal imputation dosage data, using a range of  $P$ -value thresholds for SNP inclusion<sup>66</sup> ( $5 \times 10^{-8}$ ,  $1 \times 10^{-5}$ , 0.001, 0.05 and 0.5). In this way, we can assess the presence of a progressively increasing signal-to-noise ratio in relation to the number of markers included<sup>67</sup>. As in the PGC study, we found the best  $P$ -value threshold for discrimination to be 0.05 and report highly significant polygenic overlap between the INDEPENDENT PGC and CLOZUK samples ( $P < 1 \times 10^{-300}$ , Nagelkerke  $r^2 = 0.12$ ; Supplementary Table 2), confirming the validity of combining the datasets. For comparison with other studies, we also report polygenic variance on the liability scale<sup>68</sup>, which amounted to 5.7% for CLOZUK at the 0.05  $P$ -value threshold (Supplementary Table 2). As in the PGC study, the limited  $r^2$  and area under the receiver operating characteristic curve (AUROC) obtained by this analysis restrict the current clinical utility of these scores in schizophrenia.

**Gene set analysis.** To assess the enrichment of sets of functionally related genes, we used MAGMA v1.03<sup>30</sup> on the CLOZUK + PGC meta-analysis summary statistics. From these, we excluded the xMHC region for its complex LD and the X chromosome given its smaller sample size. In the resulting data, gene-wide  $P$  values were calculated by combining the  $P$  values of all SNPs inside genes after accounting for LD and outliers. This was performed allowing for a window of 35 kb upstream and 10 kb downstream of each gene to capture the signal of nearby SNPs that could fall in regulatory regions<sup>69,70</sup>. Next, we calculated competitive gene set  $P$  values on the gene-wide  $P$  values after accounting for gene size, gene set density and LD between genes. For multiple-testing correction in each gene set collection, an FWER<sup>71</sup> was computed using 100,000 resamplings.

We performed sequential analyses using the following approaches:

1. **LoF-intolerant genes.** We tested the enrichment of the LoF-intolerant genes described by ExAC<sup>21</sup>. This set comprised all genes defined in the ExAC database as having a probability of LoF intolerance (pLI) statistic higher than 90%. Although these genes do not form part of cohesive biological processes or phenotypes, they have previously been found to be highly expressed across tissues and developmental stages<sup>21</sup>. Also, they are enriched for hub proteins<sup>72</sup>, which makes them interesting candidates for involvement in the 'evolutionary canalization' processes that have been proposed to lead to pleiotropic, complex disorders<sup>73</sup>.
2. **CNS-related genes.** These gene sets were compiled in our recent study<sup>30</sup> and include 134 gene sets related to different aspects of CNS function and development. These include, among others, gene sets that have been implicated in schizophrenia by at least two independent large-scale sequencing studies<sup>8,31</sup>: targets of FMRP<sup>32</sup>, constituents of the *N*-methyl-D-aspartate receptor (NMDAR)<sup>33</sup> and activity-regulated cytoskeleton-associated protein complexes (ARCs<sup>75,76</sup>), as well as CNS and behavioral gene sets from MGI database version 6<sup>35</sup>.
3. **Genes identified by data-driven analysis.** The final systems genomic analysis was designed as an 'agnostic' approach, with the aim of integrating a large number of gene sets from different public sources, not necessarily conceptually related to psychiatric disorders, as this has been successful elsewhere<sup>70,77</sup>. We conducted this analysis to test whether additional gene sets were associated in addition to those from the 134 CNS-related gene sets. For this, first we merged together the LoF-intolerant gene set and the 134 sets in the CNS-related collection. Second, we selected additional gene set sources to encompass a comprehensive collection of biochemical pathways and gene regulatory interaction networks: 2,693 gene sets with direct experimental evidence and a size of 10–200 genes<sup>70</sup> were extracted from Gene Ontology (GO<sup>78</sup>) database release 01/02/2016; 1,787 gene sets were extracted from the fourth ontology level of MGI database version 6<sup>35</sup>; 1,585 gene sets were extracted from REACTOME<sup>79</sup> version 55; 290 gene sets were extracted from KEGG<sup>80</sup> release 04/2015; and 187 gene sets were extracted from OMIM<sup>81</sup> release 01/02/2016.

The total number of gene sets included was 6,677.

Detailed results of the analyses of the CNS-related and data-driven collection are given in Supplementary Tables 9 and 10. Reported numbers of genes in each gene set are those with available data in the meta-analysis. This may differ from the

original gene set description, as some genic regions had null or poor SNP coverage. Following the data-driven gene set analysis as described, we also conducted analysis adjusting for our CNS-related gene sets to determine whether the data-driven analysis was contributing additional findings.

**Partitioned heritability analysis of gene sets.** It is known that the power of a gene set analysis is closely related to the total heritability of the phenotype and the specific heritability attributable to the tested gene set<sup>82</sup>. To assess the heritability explained by the genes carried forward after the main gene set analysis, LD Score was again used to compute a partitioned heritability estimate of CLOZUK + PGC using the gene sets as SNP annotations. As in the MAGMA analysis, the xMHC region was excluded from the summary statistics. These were also trimmed to contain no indels and only markers with INFO > 0.9 and MAF > 0.01, for a total of 4.64 million SNPs. As a recognized caveat of this procedure is that model misspecification can inflate the partitioned heritability estimates<sup>26</sup>, all gene sets were annotated twice: once using their exact genomic coordinates (extracted from the NCBI RefSeq database<sup>83</sup>) and another time with putative regulatory regions taken into account using the same upstream/downstream windows as in the MAGMA analyses. Additionally, all SNPs not directly covered by our gene sets of interest were explicitly included into other annotations ('non-genic', 'genic but not LoF intolerant') on the basis of their genomic location. Finally, the 'baseline' set of 53 annotations from Finucane et al.<sup>26</sup>, which recapitulates important molecular properties such as presence of enhancers or phylogenetic conservation, was also incorporated in the model. All of these annotations were then tested jointly for heritability enrichment. We note that using exact genic coordinates or adding regulatory regions made little difference to the estimated enrichment of our gene sets; thus, throughout the manuscript, we report the latter for consistency with the gene set analyses (Fig. 2 and Supplementary Table 8).

**Natural selection analyses.** We aimed to explore the hypothesis that some form of natural selection is linked to the maintenance of common genetic risk in schizophrenia<sup>12,84,85</sup>. To do this, for all SNPs included in the CLOZUK + PGC meta-analysis summary statistics, we obtained four different genome-wide metrics of positive selection (iHS<sup>86</sup>, XP-EHH<sup>87</sup>, CMS88 and CLR<sup>28</sup>), one of background selection (*B* statistic<sup>29</sup>, postprocessed by Huber et al.<sup>28</sup>) and one of Neanderthal introgression (average posterior probability LA<sup>89</sup>). The use of different statistics is motivated by the fact that each of them is tailored to detect a particular selective process that acted on a particular timeframe (see Vitti et al.<sup>51</sup> for a review). For example, iHS and CMS are based on the inference of abnormally long haplotypes and thus are better powered to detect recent selective sweeps that occurred during the last ~30,000 years<sup>88</sup>, such as those linked to lactose tolerance or pathogen response<sup>90</sup>. On the other hand, CLR incorporates information about the spatial pattern of genomic variability (the site frequency spectrum<sup>91</sup>) and corrects explicitly for evidence of BGS, thus being able to detect signals from 60,000 to 240,000 years ago<sup>28</sup>. The *B* statistic uses phylogenetic information from other primates (chimpanzee, gorilla, orangutan and rhesus macaque) to infer the reduction in allelic diversity that exists in humans as a consequence of purifying selection on linked sites over evolutionary time frames<sup>92</sup>. As the effects of background selection on large genomic regions can mimic those of positive selection<sup>46</sup>, it is possible that the *B* statistic might amalgamate both, although the rather large diversity reduction that it infers for the human genome as a whole suggests that any bias due to positive selection is likely to be minor<sup>93</sup>. Finally, XP-EHH is a haplotype-based statistic that compares two population samples, and its power is thus increased for alleles that have suffered differential selective pressures since those populations diverged<sup>90</sup>. Although methodologically different, LA has a similar rationale by comparing human and Neanderthal genomes<sup>89</sup>, to infer the probability of each human haplotype having been the result of an admixture event with Neanderthals.

For this work, CLR, CMS, the *B* statistic and LA were retrieved directly from their published references and lifted over to GRCh37 genomic coordinates if required using the Ensembl LiftOver tool<sup>94,95</sup>. As the available genome-wide measures of iHS and XP-EHH were based on HapMap 3 data<sup>96</sup>, both statistics were recalculated with the HAPBIN<sup>97</sup> software directly on the EUR superpopulation of the 1KGp3 dataset, with the AFR superpopulation used as the second population for XP-EHH. Taking advantage of the fine-scale genomic resolution of these statistics (between 1–10 kb), all SNP positions present in CLOZUK + PGC were assigned a value for each measure, either directly (if the position existed in the lifted-over data) or by linear interpolation. To simplify the interpretation of our results, all measures were transformed before further analyses to a common scale, in which larger values indicate stronger effect of selection or increased probability of introgression. For example, the BGS *B* statistic, for which values of zero indicate the strongest effect (see Charlesworth<sup>45</sup> for its theoretical derivation), was included in all our analyses as  $1 - B$ , which we termed 'BGS intensity'.

Heritability enrichment of these statistics was tested by the LD Score partitioned heritability procedure. We derived binary annotations from the natural selection metrics by dichotomizing at extreme cutoffs defined by the top 2%, 1% and 0.5% of the values of each metric in the full set of SNPs. This approach is widely used in evolutionary genomics, owing to the difficulty of setting specific thresholds to define regions under selection<sup>28,51</sup>. Consistent with the previously

described LDSR partitioned heritability protocol, enrichment was estimated with all binary annotations included in a model with multiple categories that represent important genomic features. This model included the 3 main categories of our set-based analysis ('non-genic', 'genic' and 'LoF intolerant'), 2 categories based on genomic regions with outlying LD patterns (recombination hotspots and coldspots)<sup>98</sup> and the 53 'baseline' categories of Finucane et al.<sup>26</sup>.

We then derived the  $\tau_c$  coefficient<sup>26</sup> (and associated *P* value) of the significantly enriched natural selection annotations (i.e., the background selection metric). This represents the enrichment of an annotation over and above the enrichment of all other annotations, which is a conservative approach, as most of the categories in our model are partially overlapping. To increase our power and for additional validation, we noted that LD Score allows testing of the full range of quantitative metrics, in an extension of the partitioned heritability framework. Results of this analysis are reported in Supplementary Table 8.

**Analysis of other phenotypes.** To explore the specificity of our natural selection results, we retrieved data from other well-powered GWAS of complex traits. We selected three phenotypes for which (i) the genome-wide summary statistic data were publicly available, (ii) the sample size was larger than 50,000 individuals, (iii) the phenotype has minimal impact on fecundity<sup>99–101</sup> (and hence the traits behave as neutral or approximately neutral to selection) and (iv) summary statistics were considered adequate for LD Score analysis based on baseline *z* scores > 4<sup>26,102</sup> (Supplementary Table 8). The phenotypes chosen were Alzheimer's disease<sup>103</sup>, neuroticism<sup>104</sup> and type 2 diabetes<sup>105</sup>. For the LD Score analyses, as the public release of these statistics did not include imputation INFO scores at the time of this study, we restricted the set of SNPs to those included in the HapMap 3 project<sup>96</sup>, as recommended<sup>61</sup>. To facilitate comparison with the schizophrenia results, we also restricted our schizophrenia summary statistic data to these SNPs and repeated the analyses above using BGS as a binary (top 2%) and quantitative trait.

We also employed MAGMA on the summary statistics of these additional phenotypes to examine whether the LoF-intolerant gene set enrichment displayed specificity to schizophrenia, after excluding the xMHC and *APOE* regions.

**Fine-mapping, Hi-C and SMR.** Accurately locating causal genes ('fine-mapping') for complex disorders is a challenge to GWAS and usually requires multiple approaches<sup>105</sup>. To highlight credibly causal variants, we used FINEMAP v1.1<sup>39</sup> at each of the 145 identified loci (Supplementary Table 3), selecting variants with a cumulative posterior probability of 95%. These were then annotated with ANNOVAR<sup>40</sup> release 2016Feb1 (Supplementary Table 11). We mapped the SNPs with a FINEMAP posterior probability higher than 0.5 to the developing brain Hi-C data generated by Won et al.<sup>41</sup>, following the methodology described therein, which allowed us to implicate genes by chromatin interactions instead of solely chromosomal position (Supplementary Table 12). We compiled results from the eQTL analysis of the CommonMind Consortium post-mortem brain tissues<sup>44</sup>. This included 15,782 genes, which were curated to remove any genes with FPKM = 0 across > 10% of individuals. All the SNPs from the meta-analysis data were mapped to the eQTL data using rs numbers, position and allele matching. Both datasets were analyzed together using SMR<sup>43</sup>, which resulted in 4,276 genes showing eQTLs with overlapping SNPs and genome-wide significant *P* values (Supplementary Table 13).

**URLS.** CLOZUK + PGC2 meta-analysis summary statistics, <http://walters.pscm.cf.ac.uk/>; CRESTAR Consortium, <http://www.crestar-project.eu/>; Wellcome Trust Case Control Consortium, <http://www.wtccc.org.uk/>; People of the British Isles project, <http://www.peopleofthebritishisles.org/>; Mouse Genome Informatics (MGI), <http://www.informatics.jax.org/>; Psychiatric Genomics Consortium, <http://www.med.unc.edu/pgc/>; 1000 Genomes IBD segment sharing within and between populations, [http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/ibd\\_by\\_pair/](http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/ibd_by_pair/).

**Life Sciences Reporting Summary.** Further information on experimental design is available in the Life Sciences Reporting Summary.

**Data availability.** The gene content of the CNS-related gene sets that survived conditional analysis (significant) is given in MAGMA format in the Supplementary Data. Summary statistics from the CLOZUK + PGC2 GWAS are available for download (see URLs).

## References

- Peloso, G. M. & Lunetta, K. L. Choice of population structure informative principal components for adjustment in a case-control study. *BMC Genet.* **12**, 64 (2011).
- Pirinen, M., Donnelly, P. & Spencer, C. C. A. Including known covariates can reduce power to detect genetic effects in case-control studies. *Nat. Genet.* **44**, 848–851 (2012).
- Bouaziz, M., Ambroise, C. & Guedj, M. Accounting for population stratification in practice: a comparison of the main strategies dedicated to genome-wide association studies. *PLoS One* **6**, e28845 (2011).

59. Tucker, G., Price, A. L. & Berger, B. Improving the power of GWAS and avoiding confounding from population stratification with PC-Select. *Genetics* **197**, 1045–1049 (2014).
60. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
61. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
62. Perälä, J. et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch. Gen. Psychiatry* **64**, 19–28 (2007).
63. McGrath, J., Saha, S., Chant, D. & Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol. Rev.* **30**, 67–76 (2008).
64. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
65. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. *Nat. Genet.* **43**, 969–976 (2011).
66. Tansey, K. E. et al. Common alleles contribute to schizophrenia in CNV carriers. *Mol. Psychiatry* **21**, 1085–1089 (2015).
67. Dudbridge, F. Polygenic epidemiology. *Genet. Epidemiol.* **40**, 268–272 (2016).
68. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genet. Epidemiol.* **36**, 214–224 (2012).
69. Maston, G. A., Evans, S. K. & Green, M. R. Transcriptional regulatory elements in the human genome. *Annu. Rev. Genomics Hum. Genet.* **7**, 29–59 (2006).
70. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. *Nat. Neurosci.* **18**, 199–209 (2015).
71. Cox, D. D. & Lee, J. S. Pointwise testing with functional data using the Westfall–Young randomization method. *Biometrika* **95**, 621–634 (2008).
72. Batada, N. N., Hurst, L. D. & Tyers, M. Evolutionary and physiological importance of hub proteins. *PLoS Comput. Biol.* **2**, e88 (2006).
73. Parikshak, N. N., Gandal, M. J. & Geschwind, D. H. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. *Nat. Rev. Genet.* **16**, 441–458 (2015).
74. Pocklington, A. J., Cumsiskey, M., Armstrong, J. D. & Grant, S. G. N. The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour. *Mol. Syst. Biol.* **2**, 2006.0023 (2006).
75. Fernández, E. et al. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. *Mol. Syst. Biol.* **5**, 269 (2009).
76. Kirov, G. et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Mol. Psychiatry* **17**, 142–153 (2012).
77. Pers, T. H. et al. Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes. *Hum. Mol. Genet.* **25**, 1247–1254 (2016).
78. Gene Ontology Consortium. Gene Ontology Consortium: going forward. *Nucleic Acids Res.* **43**, D1049–D1056 (2015).
79. Fabregat, A. et al. The Reactome Pathway Knowledgebase. *Nucleic Acids Res.* **44** (D1), D481–D487 (2016).
80. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res.* **44** (D1), D457–D462 (2016).
81. Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F. & Hamosh, A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. *Nucleic Acids Res.* **43**, D789–D798 (2015).
82. de Leeuw, C. A., Neale, B. M., Heskes, T. & Posthuma, D. The statistical properties of gene-set analysis. *Nat. Rev. Genet.* **17**, 353–364 (2016).
83. O’Leary, N. A. et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* **44** (D1), D733–D745 (2016).
84. van Dongen, J. & Boomsma, D. I. The evolutionary paradox and the missing heritability of schizophrenia. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **162B**, 122–136 (2013).
85. Xu, K., Schadt, E. E., Pollard, K. S., Roussos, P. & Dudley, J. T. Genomic and network patterns of schizophrenia genetic variation in human evolutionary accelerated regions. *Mol. Biol. Evol.* **32**, 1148–1160 (2015).
86. Voight, B. F., Kudaravalli, S., Wen, X. & Pritchard, J. K. A map of recent positive selection in the human genome. *PLoS Biol.* **4**, e72 (2006).
87. Sabeti, P. C. et al. Genome-wide detection and characterization of positive selection in human populations. *Nature* **449**, 913–918 (2007).
88. Grossman, S. R. et al. Identifying recent adaptations in large-scale genomic data. *Cell* **152**, 703–713 (2013).
89. Sankararaman, S. et al. The genomic landscape of Neanderthal ancestry in present-day humans. *Nature* **507**, 354–357 (2014).
90. Sabeti, P. C. et al. Positive natural selection in the human lineage. *Science* **312**, 1614–1620 (2006).
91. Ronen, R., Udpa, N., Halperin, E. & Bafna, V. Learning natural selection from the site frequency spectrum. *Genetics* **195**, 181–193 (2013).
92. Nordborg, M., Charlesworth, B. & Charlesworth, D. The effect of recombination on background selection. *Genet. Res.* **67**, 159–174 (1996).
93. Fu, W. & Akey, J. M. Selection and adaptation in the human genome. *Annu. Rev. Genomics Hum. Genet.* **14**, 467–489 (2013).
94. Zhao, H. et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies. *Bioinformatics* **30**, 1006–1007 (2014).
95. Cunningham, F. et al. Ensembl 2015. *Nucleic Acids Res.* **43**, D662–D669 (2015).
96. Altshuler, D. M. et al. Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52–58 (2010).
97. Maclean, C. A., Chue Hong, N. P. & Prendergast, J. G. hapbin: an efficient program for performing haplotype-based scans for positive selection in large genomic datasets. *Mol. Biol. Evol.* **32**, 3027–3029 (2015).
98. Hussin, J. G. et al. Recombination affects accumulation of damaging and disease-associated mutations in human populations. *Nat. Genet.* **47**, 400–404 (2015).
99. Ptok, U., Barkow, K. & Heun, R. Fertility and number of children in patients with Alzheimer’s disease. *Arch. Womens Ment. Health* **5**, 83–86 (2002).
100. Whitworth, K. W., Baird, D. D., Stene, L. C., Skjaerven, R. & Longnecker, M. P. Fecundability among women with type 1 and type 2 diabetes in the Norwegian Mother and Child Cohort Study. *Diabetologia* **54**, 516–522 (2011).
101. Jokela, M. Birth-cohort effects in the association between personality and fertility. *Psychol. Sci.* **23**, 835–841 (2012).
102. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
103. Lambert, J.-C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. *Nat. Genet.* **45**, 1452–1458 (2013).
104. Smith, D. J. et al. Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci. *Mol. Psychiatry* **21**, 749–757 (2016).
105. Mahajan, A. et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat. Genet.* **46**, 234–244 (2014).

## Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work we publish. This form is published with all life science papers and is intended to promote consistency and transparency in reporting. All life sciences submissions use this form; while some list items might not apply to an individual manuscript, all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### ▶ Experimental design

#### 1. Sample size

Describe how sample size was determined.

Sample size was not pre-specified. Genetic and clinical validation of the samples is reported in the Supplementary Note (P2-4).

#### 2. Data exclusions

Describe any data exclusions.

See Supplementary Note: P2 (phenotype-driven exclusions) and P4-5 (genotype-driven exclusions).

#### 3. Replication

Describe whether the experimental findings were reliably reproduced.

Replication of the novel GWAS findings was carried out in an independent sample (5,762 cases and 154,224 controls). Results and methodological details are shown in P4, Online Methods and Supplementary Note.

#### 4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

No randomization method was used.

#### 5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

Researchers were not blinded to case/control status.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

#### 6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- The test results (e.g.  $p$  values) given as exact values whenever possible and with confidence intervals noted
- A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

## ► Software

Policy information about [availability of computer code](#)

### 7. Software

Describe the software used to analyze the data in this study.

PLINK v1.9 (Jun 2015), SHAPEIT v2 (r837), IMPUTE v2.3.2, EIGENSOFT v6, LDSC v1, MAGMA v1.03, ENSEMBL Assembly Converter (LiftOver r86), HAPBIN v1.10, Finemap v1.1, ANNOVAR (Feb 2016), SMR v0.6. All software and versions are stated throughout Online Methods.

For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The *Nature Methods* [guidance for providing algorithms and software for publication](#) may be useful for any submission.

## ► Materials and reagents

Policy information about [availability of materials](#)

### 8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

No unique materials were used.

### 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

No antibodies were used.

### 10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

No eukaryotic cell lines were used.

b. Describe the method of cell line authentication used.

No eukaryotic cell lines were used.

c. Report whether the cell lines were tested for mycoplasma contamination.

No eukaryotic cell lines were used.

d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

No eukaryotic cell lines were used.

## ► Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

### 11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

No animals were used.

Policy information about [studies involving human research participants](#)

### 12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

Participants are described in Supplementary Note (P2-4, P17-19).